HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $210,711 | -0.4% | 5,516 | -17.5% | 0.00% | -25.0% |
Q1 2023 | $211,512 | -32.6% | 6,685 | +21.2% | 0.00% | -33.3% |
Q4 2022 | $313,747 | +29.6% | 5,514 | +0.3% | 0.01% | +20.0% |
Q2 2022 | $242,000 | -28.6% | 5,500 | -35.3% | 0.01% | -28.6% |
Q1 2022 | $339,000 | -0.9% | 8,500 | 0.0% | 0.01% | -12.5% |
Q4 2021 | $342,000 | -1.2% | 8,500 | 0.0% | 0.01% | -11.1% |
Q3 2021 | $346,000 | -10.4% | 8,500 | 0.0% | 0.01% | -18.2% |
Q2 2021 | $386,000 | +9.0% | 8,500 | 0.0% | 0.01% | 0.0% |
Q1 2021 | $354,000 | -2.5% | 8,500 | 0.0% | 0.01% | -15.4% |
Q4 2020 | $363,000 | +62.8% | 8,500 | 0.0% | 0.01% | +30.0% |
Q3 2020 | $223,000 | -16.8% | 8,500 | – | 0.01% | -9.1% |
Q2 2020 | $268,000 | +48.9% | 0 | -100.0% | 0.01% | +22.2% |
Q1 2020 | $180,000 | +1.7% | 10,000 | 0.0% | 0.01% | +28.6% |
Q4 2019 | $177,000 | +14.2% | 10,000 | 0.0% | 0.01% | -12.5% |
Q3 2019 | $155,000 | -9.9% | 10,000 | 0.0% | 0.01% | -27.3% |
Q2 2019 | $172,000 | – | 10,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |